Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

Strakowski, Stephen M.; Johnson, Jacqueline L.; DelBello, Melissa P.; Hamer, Robert M.; Green, Alan I.; Tohen, Mauricio; Lieberman, Jeffrey A.; Glick, Ira; Patel, Jayendra K.; HGDH Research Group,

doi:10.1016/j.schres.2005.04.017

« Previous Next »Schizophrenia Research
Volume 78, Issue 2 , Pages 161-169, 15 October 2005

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

Stephen M. Strakowski
- Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way (ML0583), Cincinnati, OH 45267-0583, USA
- Corresponding author. Tel.: +1 513 558 2958; fax: +1 513 558 7164.
Jacqueline L. Johnson
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Melissa P. DelBello
- Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way (ML0583), Cincinnati, OH 45267-0583, USA
Robert M. Hamer
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Alan I. Green
- Dartmouth Medical School, Lebanon, NH, USA
Mauricio Tohen
- Eli Lilly and Co., Lilly Research Laboratories, Indianapolis, IN, USA
- McLean Hospital, Harvard Medical School, Belmont, MA, USA
Jeffrey A. Lieberman
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Columbia University, School of Medicine, New York, NY, USA
Ira Glick
- Stanford University School of Medicine, CA, USA
Jayendra K. Patel
- University of Massachusetts Medical Center, MA, USA
HGDH Research Group
- This paper was based in part on results from the study of the Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis by the HGDH Study Group sponsored by Eli Lilly and Company. The HGDH research group consists of Drs. Jeffrey Lieberman and Diana Perkins, Dept. of Psychiatry, Univ. of North Carolina School of Medicine, NC, USA; Drs. Joseph P. McEvoy, Cecil Charles and Richard Keefe, John Ulmstead Hospital, Duke University Health System, NC, USA; Drs. Robert B. Zipursky and Zafiris J. Daskalakis, Dept. of Psychiatry, University of Toronto School of Medicine, Ontario, Canada; Dr. Alan I. Green, Massachusetts Mental Health Center, Harvard Medical School, MA, USA; Dr. Charles B. Nemeroff, Dept. of Psychiatry, Emory University School of Medicine, GA, USA; Prof. Robin Murray and Dr. Tonmoy Sharma, Institute of Psychiatry, UK; Dr. Raquel E. Gur, Dept of Psychiatry, Univ. of Pennsylvania Medical Center, PA, USA; Drs. Bruce Cohen and Franca Centorrino, McLean Hospital, Harvard Medical School, Belmont, MA, USA; Prof. Dr. R.S. Kahn, University Hospital, Utrecht, The Netherlands; Drs. Wayne Goodman and John Kuldau, Dept. of Psychiatry, Univ. of Florida, FL, USA; Drs. Anthony J. Rothschild and Jayendra K. Patel, Dept. of Psychiatry, Univ. of Massachusetts Medical Center, MA, USA; Dr. Stephen M. Strakowski, Dept. of Psychiatry, Univ. of Cincinnati, OH, USA; Dr. Ira Glick, Dept. of Psychiatry, Stanford University School of Medicine, CA, USA; Dr. John De Quardo, Dept. of Psychiatry, Univ. of Michigan Medical Center, MI, USA; Drs. Gary Tollefson, Todd Sanger, Mauricio Tohen, Lilly Research Laboratories, IN, USA.